U.S., June 14 -- ClinicalTrials.gov registry received information related to the study (NCT07021261) titled 'Comparing UTD2 Combined With Capecitabine to Capecitabine as Adjuvant Therapy for Non-pCR TNBC Patients' on May 18.
Brief Summary: Evaluate the IDFS rate, overall survival (OS) rate, and safety profile of UTD2 combined with capecitabine versus capecitabine monotherapy as adjuvant therapy for triple-negative early breast cancer patients who did not achieve pathological complete response (pCR) after neoadjuvant therapy.
Study Start Date: June 16
Study Type: INTERVENTIONAL
Condition:
Breast Cancer
TNBC
Intervention:
DRUG: Utidelone plus capecitabine
UTD2 50 mg/m²/day orally on Days 1-5, repeated every 21 days for 2 years; C...